ApprovalTrail

Approval · Notice of Compliance 8682 · 2007

STREPTASE: Notice of Compliance 8682

Issued March 30, 2007

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
8682
Date
March 30, 2007
Company
Csl Behring Canada IncOttawa, Ontario, Canada
Product type
Biologic
Submission
New Drug Submission (NDS)
Submission class
Admin
Reason
Manufacturer name change
Therapeutic class
Fibrinolytic agent

Products in this notice

BrandDINStatus today
STREPTASE02018993Cancelled Post Market
STREPTASE02019000Cancelled Post Market
STREPTASE02019019Cancelled Post Market

Medicinal ingredients